HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

The 3p21.3 tumor suppressor NPRL2 plays an important role in cisplatin-induced resistance in human non-small-cell lung cancer cells.

Abstract
NPRL2 is one of the novel candidate tumor suppressor genes identified in the human chromosome 3p21.3 region. The NPRL2 has shown potent tumor suppression activity in vitro and in vivo and has been suggested to be involved in DNA mismatch repair, cell cycle checkpoint signaling, and regulation of the apoptotic pathway. In this study, we analyzed the endogenous expression of the NPRL2 protein and the cellular response to cisplatin in 40 non-small-cell lung cancer cell lines and found that expression of NPRL2 was significantly and reciprocally correlated to cisplatin sensitivity, with a Spearman correlation coefficient of -0.677 (P < 0.00001). Exogenously introduced expression of NPRL2 by N-[1-(2,3-dioleoyloxyl)propyl]-NNN-trimethylammoniummethyl sulfate:cholesterol nanoparticle-mediated gene transfer significantly resensitized the response to cisplatin, yielding a 40% greater inhibition of tumor cell viability and resulting in a 2- to 3-fold increase in induction of apoptosis by activation of multiple caspases in NPRL2-transfected cells compared with untransfected cells at an equal dose of cisplatin. Furthermore, a systemic treatment with a combination of NPRL2 nanoparticles and cisplatin in a human H322 lung cancer orthotopic mouse model significantly enhanced the therapeutic efficacy of cisplatin and overcame cisplatin-induced resistance (P < 0.005). These findings implicate the potential of NPRL2 as a biomarker for predicting cisplatin response in lung cancer patients and as a molecular therapeutic agent for enhancing response and resensitizing nonresponders to cisplatin treatment.
AuthorsKentaro Ueda, Hiroyuki Kawashima, Shoichiro Ohtani, Wu-Guo Deng, Murali Ravoori, Jim Bankson, Boning Gao, Luc Girard, John D Minna, Jack A Roth, Vikas Kundra, Lin Ji
JournalCancer research (Cancer Res) Vol. 66 Issue 19 Pg. 9682-90 (Oct 01 2006) ISSN: 1538-7445 [Electronic] United States
PMID17018626 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, Non-P.H.S.)
Chemical References
  • Antineoplastic Agents, Alkylating
  • Fatty Acids, Monounsaturated
  • NPRL2 protein, human
  • Neoplasm Proteins
  • Quaternary Ammonium Compounds
  • Recombinant Fusion Proteins
  • Tumor Suppressor Proteins
  • Cholesterol
  • 1,2-dioleoyloxy-3-(trimethylammonium)propane
  • Cisplatin
Topics
  • Animals
  • Antineoplastic Agents, Alkylating (pharmacology)
  • Apoptosis (drug effects)
  • Carcinoma, Non-Small-Cell Lung (genetics, metabolism, pathology)
  • Cell Line, Tumor (drug effects, metabolism)
  • Cholesterol (administration & dosage)
  • Cisplatin (pharmacology)
  • Drug Resistance, Neoplasm (drug effects)
  • Fatty Acids, Monounsaturated (administration & dosage)
  • Female
  • Gene Transfer Techniques
  • Genetic Vectors (pharmacology)
  • Humans
  • Lung Neoplasms (genetics, metabolism, pathology)
  • Mice
  • Mice, Nude
  • Nanoparticles
  • Neoplasm Proteins (genetics, physiology)
  • Quaternary Ammonium Compounds (administration & dosage)
  • Random Allocation
  • Recombinant Fusion Proteins (physiology)
  • Tumor Stem Cell Assay
  • Tumor Suppressor Proteins (genetics, physiology)
  • Xenograft Model Antitumor Assays

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: